PlainRecalls
FDA Drug Low Class III Terminated

Deferoxamine Mesylate for injection, USP, Single-use Vial, 500 mg/vial, 10 mL vial. Intravenous, Intramuscular, Subcutaneous Use, Rx Only, Hospira, Inc., Lake Forest IL USA, NDC 0406-2336-10.

Reported: October 11, 2017 Initiated: July 12, 2017 #D-0001-2018

Product Description

Deferoxamine Mesylate for injection, USP, Single-use Vial, 500 mg/vial, 10 mL vial. Intravenous, Intramuscular, Subcutaneous Use, Rx Only, Hospira, Inc., Lake Forest IL USA, NDC 0406-2336-10.

Reason for Recall

CGMP Deviations: Firm failed to control impurity for color change at the API stage.

Details

Recalling Firm
Pfizer Inc.
Units Affected
32,276 10 mL vials
Distribution
Nationwide
Location
New York, NY

Frequently Asked Questions

What product was recalled?
Deferoxamine Mesylate for injection, USP, Single-use Vial, 500 mg/vial, 10 mL vial. Intravenous, Intramuscular, Subcutaneous Use, Rx Only, Hospira, Inc., Lake Forest IL USA, NDC 0406-2336-10.. Recalled by Pfizer Inc.. Units affected: 32,276 10 mL vials.
Why was this product recalled?
CGMP Deviations: Firm failed to control impurity for color change at the API stage.
Which agency issued this recall?
This recall was issued by the FDA Drug on October 11, 2017. Severity: Low. Recall number: D-0001-2018.